Ophthalmic compositions containing diglycine

• US 8,664,180 B2
• Filed: 02/06/2012
• Issued: 03/04/2014
• Est. Priority Date: 02/06/2012
• Status: Active Grant

• Current Assignee: Bausch & Lomb Incorporated (Bausch Health Cos., Inc.)
• Original Assignee: Bausch & Lomb Incorporated (Bausch Health Cos., Inc.)
• Inventors: Burke, Susan E., Xia, Erning, Scheuer, Catherine A., Venkatesh, Srini
• Primary Examiner(s): FAY, ZOHREH A
• Application Number:
  US13/366,398
• Publication Number:
  US 20130202547A1
• Time in Patent Office: 757 Days
• Field of Search: 514/19, 514/642, 514/912
• US Class Current: 514/19
• CPC Class Codes: A01N 33/12 Quaternary ammonium compounds
• CPC Class Codes: A01N 37/46 N-acyl derivatives
• CPC Class Codes: A01N 47/44 Guanidine; Derivatives thereof
• CPC Class Codes: A01N 55/08 containing boron
• CPC Class Codes: A61L 12/142 Polymeric biguanides

Abstract

Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 0.01 ppm to 3 ppm poly(hexamethylene biguanide); 1 ppm to 10 ppm α-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl)ammonium chloride; and 0.1% w/v to 2% w/v of one or more boron buffering compounds.

Claims

1. An ophthalmic composition comprising:

0.05% w/v to 2% w/v diglycine or a salt thereof;

0.01 ppm to 3 ppm poly(hexamethylene biguanide);

1 ppm to 10 ppm α

-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-ω

-tris(2-hydroxyethyl)ammonium chloride; and

0.1% w/v to 2% w/v of one or more boron buffering compounds.

2. The composition of claim 1 further comprising hyaluronic acid or a salt thereof.

3. The ophthalmic composition of claim 1 further comprising a sulphobetaine surfactant of the formula

4. The composition of claim 1 further comprising dexpanthenol, sorbitol, propylene glycol, aspartic acid, glycolic acid, 2-amino-2-methyl-1,3-propanediol or any mixture thereof.

5. The composition of claim 1 further comprising a hydroxypropylmethyl cellulose.

6. The composition of claim 1 further comprising a disuccinate of formula

7. The composition of claim 1 wherein the one or more boron buffering compounds include boric acid from 0.15% w/v to 0.6% w/v, sodium or potassium borate from 0.05% w/v to 0.5% w/v, and the diglycine from 0.1% w/v to 0.7% w/v.

8. An ophthalmic composition comprising:

buffering compounds including boric acid from 0.15% w/v to 0.6% w/v, sodium or potassium borate from 0.05% w/v to 0.5% w/v, and diglycine from 0.1% w/v to 0.7% w/v;

0.01 ppm to 3 ppm poly(hexamethylene biguanide); and

hyaluronic acid or a salt thereof, which is present from 0.05 wt. % to 0.2 wt. %.

9. The composition of claim 8 further comprising 1 ppm to 10 ppm of α

-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-ω

-tris(2-hydroxyethyl)ammonium chloride.

10. The composition of claim 8 further comprising a disuccinate of formula